Clinical Trial Update: Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating chemotherapy with or without bevacizumab for malignant mesothelioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Mesothelioma
• Localized Malignant Mesothelioma
• Malignant Mesothelioma
• Sarcomatoid Mesothelioma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Status: COMPLETED